Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland.
Brock E, Moschovitis G, Maeder M, Pfister O. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland. Pharmacoecon Open 2022; 6:735-743.
Jun 10, 2022
Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland.
Jun 10, 2022
Pharmacoecon Open 2022; 6:735-743
Brock Elisabeth, Moschovitis Giorgio, Maeder Micha, Pfister Otmar
more
